Donald Trump appeared drowsy during a Cabinet meeting after a late-night Truth Social spree, prompting online rumors that he ...
A medical expert claims Trump's bruised hand proves he is receiving monthly infusions for possible dementia, linking it to ...
Eisai (ESALY) and Biogen (BIIB) announced that the latest findings on time savings with continued treatment with humanized ...
Pharmaceutical Technology on MSN
Eisai seeks PMDA approval for subcutaneous Leqembi in Japan
Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...
Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025. Eisai Presents New Data on the Continued ...
With concerns growing over the burden Leqembi could impose on healthcare infrastructure, Eisai and Biogen have trotted out data for an under-the-skin version of the Alzheimer’s disease drug that may ...
Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...
WASHINGTON — U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people ...
Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback